title: Ethinylestradiol/chlormadinone acetate.
abstract: Ethinylestradiol/chlormadinone acetate 0.03/2mg (EE/CMA) is a combined monophasic contraceptive pill with antiandrogenic properties. In a large, noncomparative, multicentre trial (< or =24 cycles of treatment per woman) and two (6- and 12-cycle) postmarketing surveillance studies, EE/CMA was effective in preventing pregnancy. EE/CMA was significantly more effective than EE/levonorgestrel 0.03/0.15 mg/day in treating women with mild-to-moderate papulopustular acne of the face and related disorders in a randomised, single-blind, multicentre trial. EE/CMA was well tolerated in clinical trials and the postmarketing surveillance studies. Adverse events were those commonly reported with oral contraceptives. As expected, the most common menstrual disturbances were breakthrough bleeding, spotting and amenorrhoea.
authors.affiliation: Adis International Limited, 41 Centorian Drive, PB 65901, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz
authors.forename: Monique P
authors.initials: MP
authors.lastname: Curran
authors.forename: Antona J
authors.initials: AJ
authors.lastname: Wagstaff
mesh_terms: D002715:Chlormadinone Acetate / Q000031:analogs & derivatives / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D003277:Contraceptives, Oral, Combined / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D018849:Controlled Clinical Trials as Topic; D004359:Drug Therapy, Combination; D004717:Endometrium / Q000187:drug effects; D004997:Ethinyl Estradiol / Q000031:analogs & derivatives / Q000627:therapeutic use*; D005187:Fallopian Tubes / Q000187:drug effects / Q000502:physiology; D005260:Female; D005858:Germany; D006801:Humans; D010900:Pituitary Diseases / Q000188:drug therapy*
chemical_list: D003277:Contraceptives, Oral, Combined; C488302:ethinylestradiol-chlormadinone acetate; D002715:Chlormadinone Acetate; D004997:Ethinyl Estradiol